This year the 9th Lipidclub & Therapeutic Apheresis was held in the evocative eternal city, Rome: Difass International was pleased to actively participate in the event.
On 7th June, Dr. Mazza gave a presentation entitled "Chronic Kidney Disease as Cardiovascular Risk Predictor. Evidence Based Clinical Management." The presentation described the results of the recently published clinical trial: Efficacy and Safety of Dif1stat® for the Treatment of Secondary Dyslipidemia in Chronic Kidney Disease., September, 2013, Vol.7, No. 9, pp. 941-949 Journal of Life Sciences, ISSN 1934-7391, USA.